STAMFORD, Conn., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, will announce financial results for the third quarter ended September 30, 2014 on November 14, 2014 before the NASDAQ market open.
The Company will not be conducting a conference call in conjunction with this earnings release. Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.
About Loxo Oncology
Loxo Oncology develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo's development approach translates key scientific insights relating to the oncogenic drivers of cancer into drugs that are potent and highly selective for their intended targets. This approach is intended to allow for the development of drugs with a high probability of clinical success while reducing the time, costs and risks of drug development. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com.
CONTACT: Company: Jacob S. Van Naarden Vice President, Corporate Development and Strategy email@example.com Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 firstname.lastname@example.org Media: Karen Sharma MacDougall Biomedical Communications 781-235-3060 email@example.comSource:Loxo Oncology